All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

CCR7 as a potential therapeutic target for GvHD – results from preclinical models

Mar 18, 2020

Acute graft-versus-host disease (aGvHD) is a major complication following hematopoietic stem cell transplant (HSCT) that contributes to high non-relapse mortality. The disease process is initiated by the migration of donor T cells to the host secondary lymphoid organs and their activation by allo-antigens on host antigen-presenting cells (APC).1 CCR7, a chemokine receptor, and its ligands CCL19 and CCL21 expressed by donor T cells is critically important for lymph node specific homing and activation of T cells by APCs.2

Previous reports demonstrated that a high proportion of CCR7+ donor T-cell subsets in the graft was an independent risk factors for aGvHD and correlated with poorer outcome.3

A study published by Carlos Cuesta-Mateos and colleagues explored whether apheresis with a low proportion of CCR7+ cells or blocking the function of CCR7 with an anti-human CCR7 monoclonal antibody (mAb) could prevent or treat aGvHD in preclinical models.4


  • Apheresis samples were stained with a panel of antibodies including anti-CD45RA, anti-CD62L, anti-CD3, anti-CD4 to identify the following T cell subsets:
    • T cells considered as primary mediators of aGVHD
      • CCR7+ naïve T cells (TN)
      • central memory T cells (TCM)
    • T cells associated with responses against infections and graft-versus-leukemia (GvL) effect
      • CCR7- effector memory T cells (TEM)
      • CCR7- CD45RA+ TEM cells (TEMRA)
  • Migration and complement-dependent cytotoxicity (CDC) assays were performed on peripheral blood mononuclear cells (PBMC) from apheresis samples
  • Xenogeneic models of aGvHD were induced by engrafting human (h) PBMC in sub-lethally irradiated NSG mice

Main findings

In total, 103 donor–recipient pairs who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) were analyzed. Transplant characteristics are presented in Table 1.

Table 1. Selected transplant characteristics

BMSC, bone marrow stem cells; CsA, cyclosporin A; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; MTX, methotrexate; PBSC, peripheral blood stem cells


Patients, %

Diagnosis of the underlying disease (Relapse rate, %)

Myelodysplastic syndrome

Acute lymphoid leukemia

Acute myeloid leukemia

Hodgkin lymphoma

Non-Hodgkin lymphoma

Chronic lymphocytic leukemia

Multiple myeloma


27 (17)

9 (33)

44 (22)

9 (33)

8 (25)

2 (0)

2 (50)

Gender matching

Male to male

Female to female






Donor type

HLA-identical sibling

HLA-identical (10/10) unrelated

HLA mismatched (9/10) unrelated





Source of graft



Infused CD34+ 106/kg of recipient weight

Infused CD3+ 106/kg of recipient weight






Conditioning regimen


No Myeloablative




GvHD prophylaxis

CsA and MTX

CsA and MMF






Correlating rate of transfused CCR7+ cells with induction of GvHD in humans and mice

In patients, apheresis with < 3.6% of CD4+ CCR7+ cells showed low risk of developing aGvHD, with 87.88% (75.23–100%) of patients not developing the complication. The cut off for CD8+ CCR7+ was < 2.2% cells in the apheresis, with 88.57% (76.60–100%) of patients free from chronic (c)GvHD.

In contrast, xenograft models of GvHD demonstrated that lowering the proportion of CCR7+ cells used for apheresis failed to prevent or delay GvHD. The median overall survival (OS) was 14 days for animals engrafted with apheresis products containing ≤3% of CD4+ CCR7+ (n = 6) vs 13 days for mice with apheresis around 20% of CCR7+ cells.

Using anti-CCR7 mAb impairs CCR7+ TN and TCM cells chemotaxis and induces CDC

The addition of anti-CCR7 mAb to PBMC reduced the migration of CCR7+ TN and TCM cells stimulated with CCL19 or CCL21. CCR7 ligands and anti-CCR7 mAb did not induce responses in TEM and TEMRA cells which were CCR7-. Moreover, in vitro assays using anti-CCR7 mAb with fresh hPBMC from apheresis demonstrated strong depletion of CCR7+ but not CCR7- human TN and TCM cells via CDC.

CCR7+ T-cells are not involved in CMV reactivation and GvL effect

In patients, the levels of donor CCR7+ T cells in the apheresis did not correlate with cytomegalovirus (CMV) reactivation within the first six months after transplantation or with a relapse of the underlying disease.

Anti-hCCR7 mAb prevents aGvHD in xenograft models

In xenogenic models of aGvHD induced by engrafting of hPBMC, early administration of anti-CCR7 mAb, after hPBMC inoculation, prevented the development of aGvHD. Animals treated later than on Day 5 after engraftment had infiltration of human T cells in all tissues, which was, however, lower than in control mice.

  • In animals that started treatment two hours before engraftment and had additional four doses given every three days, there was an increased median OS with the anti-hCCR7 mAb vs control (30 days vs 12 days; p = 0.0025)
  • In animals that started treatment on Day 5 after engraftment and had additional four doses administered, anti-hCCR7 mAb was able to reverse first clinical signs of aGvHD and provide survival benefit compared to control treatment (median OS of 33 days vs 18 days; p = 0.0211)
  • In animals that started treatment on Day 3, Day 7, or Day 10 after engraftment and had additional four doses given every three days, best responses were seen at Day 3 (median OS of 26 days with anti-hCCR7 mAb vs 12 days with control; p = 0.0026) compared to Day 7 (median OS 18 days vs 12 days, respectively; p = 0.0742) and Day 10 (median OS 17 days vs 12 days, respectively; p = 0.0181)


The authors of the article demonstrated that selective targeting of CCR7 with antibodies is a feasible and promising way to prevent donor T-cell migration to secondary lymphoid organs and to reduce the severity of aGVHD. Importantly, CCR7+ T cells seem not to be involved in the GvL effect or CMV reactivation. Other than in humans, xenograft models suggest that even small amounts of CCR7+ T cells can induce GvHD. The most profound anti-aGvHD effect was observed in transplanted mice, when an anti-hCCR7 mAb was administrated within the first five days after transplantation. This novel prophylactic approach could offer a benefit to patients in haploidentical settings, who have a particularly large unmet need for safe and effective therapies preventing GvHD.

  1. Beilhack A. et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008 Mar 1;111(5):2919–28. DOI: 10.1182/blood-2007-09-112789
  2. Förster R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999 Oct 1;99(1):23–33. DOI: 10.1016/s0092-8674(00)80059-8
  3. Portero-Sainz I. et al. A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD. Bone Marrow Transplant. 2017 May;52(5):745–752. DOI: 10.1038/bmt.2016.342
  4. Cuesta-Mateos C. et al. Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease. Bone Marrow Transplant. 2020 Feb 21. DOI: 10.1038/s41409-020-0830-8